Fosun Pharma increases guarantees for subsidiaries' financing

Shanghai Fosun Pharmaceutical Group (SSE: 600196) announced increased financial guarantees for its controlling subsidiaries. The company issued new guarantees totaling CNY 165.241 million for Fosun Pharmaceutical Industry via HSBC, CNY 35 million for Fosun Pharmaceutical Industry through the Industrial Bank and CNY 20 million for Fosun Pharmaceutical Industry through the Shanghai Pudong Development Bank. Additionally, it issued a CNY 3 million guarantee for Fosun Anterjin through China CITIC Bank. The firm is also increasing guarantee amounts for existing debt with the Bank of Communications from CNY 8 million. The company also disclosed it has increased guarantee limit for Hanlin Pharmaceutical through Shanghai Pudong Development Bank to CNY 10 million, and increasing guarantee limit for Fosun Health to CNY 10 million through Hwasea Bank. As of June 12, 2025, the group's total external guarantees, primarily for its subsidiaries, amount to approximately CNY 2,472.351 million, representing 52.31% of its net assets attributable to shareholders.